- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Apotex to Announce Second Quarter Fiscal 2027 Financial Results and Host Conference Call on November 12, 2026 | 3 | CNW | ||
| 06.10. | Apotex Health Corp: Apotex closes $1,250-million senior note offering | 3 | Stockwatch | ||
| 05.10. | Apotex Health Corp. Announces Closing Of $1,250 Million Inaugural Senior Unsecured Notes Offering | 3 | CNW | ||
| 29.09. | Apotex Health Corp: Apotex Health prices $1.25-billion note offering | 1 | Stockwatch | ||
| APOTEX HEALTH Aktie jetzt für 0€ handeln | |||||
| 28.09. | Apotex Health Corp. Announces $1,250 Million Inaugural Senior Unsecured Notes Offering | 1 | CNW | ||
| 31.08. | RedHill Biopharma Divests Talicia Stake to Apotex Subsidiary for $18M | 12 | Contract Pharma | ||
| 31.08. | RedHill To Divest Talicia Business To Apotex For Upfront Cash Payment Of $18 Mln, Shares Up 139% | 2 | RTTNews | ||
| 31.08. | RedHill Divests Talicia To Apotex For Up To $53 Million To Fund Commercial Expansion | 1 | pulse2.com | ||
| 31.08. | RedHill Biopharma divests Talicia to Apotex for $18M upfront | 8 | Seeking Alpha | ||
| 31.08. | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | 695 | PR Newswire | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| 12.08. | Apotex Health Non-GAAP EPS of C$0.70, revenue of C$848M | 2 | Seeking Alpha | ||
| 12.08. | Apotex Health declares $0.06 dividend | 1 | Seeking Alpha | ||
| 12.08. | Apotex Q1 FY27 slides: strong start post-IPO, Canadian growth shines | 1 | Investing.com | ||
| 12.08. | Apotex Q1 FY27 slides: IPO strengthens balance sheet, Canada up 11% | 2 | Investing.com | ||
| 12.08. | Canada's Apotex Reports Net Loss After Going Public | - | Baystreet.ca | ||
| 12.08. | Apotex reports $38M net loss in first quarter after going public in June | 1 | BNN Bloomberg | ||
| 12.08. | Apotex Health Corp.: Apotex Announces First Quarter 2027 Results | 3.354 | PR Newswire | - Canada Delivers 11% Revenue Growth in Q1
- Adjusted EBITDA1 of $259 Million with 31% Margin
- Launch Momentum Supports FY 2027 Guidance: Upper Mid-Single Digit... ► Artikel lesen | |
| 17.07. | Apotex Health Corp: Apotex rated as investment-grade issuer by Morningstar | 1 | Stockwatch | ||
| 16.07. | Apotex secures investment grade rating, amends credit facility | 1 | Investing.com | ||
| 16.07. | Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement | 1 | CNW |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 43,480 | +0,18 % | Frist statt Freibrief: Was der EU-Pestizidbeschluss für Bayer, BASF und MustGrow Biologics bedeutet | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics. Der Rat der Europäischen Union positionierte sich am 30. September 2026 gegen unbefristete Zulassungen für synthetische Pflanzenschutzmittel... ► Artikel lesen | |
| MERCK KGAA | 146,40 | +1,42 % | Aktie wird zerlegt: BioNTech verfehlt Krebsziel - aber leben Patienten mit der Therapie länger? | © Foto: picture alliance / Laci Perenyi | Laci PerenyiDas erste Hauptziel der Krebsstudie ist verfehlt. Doch die entscheidende Frage bleibt offen: Kann BNT113 das Leben der Patienten verlängern Enthaltene... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,870 | +0,04 % | Teva: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 16,000 | -0,06 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| KARDIGAN | 13,510 | 0,00 % | Kardigan stock initiated at Outperform by William Blair on pipeline | ||
| SCHOTT PHARMA | 26,000 | +1,96 % | SCHOTT Pharma mit PAUKENSCHLAG: Kaufen Insider bereits massiv? - Unbedingt noch vor Börsenschluss lesen! | ||
| ETON PHARMACEUTICALS | 50,15 | -0,08 % | Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug | ||
| OMNIAB | 4,955 | 0,00 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| AQUESTIVE THERAPEUTICS | 4,060 | +0,25 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| BIOHAVEN | 11,805 | -0,13 % | Biohaven Ltd. - 8-K, Current Report | ||
| LB PHARMACEUTICALS | 41,000 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming Investor Events | ||
| GENERATE BIOMEDICINES | 12,905 | +0,04 % | Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market | ||
| BRIGHT MINDS BIOSCIENCES | 55,21 | 0,00 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 19,240 | -0,21 % | Seaport Therapeutics, Inc.: Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress | First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing Detailed... ► Artikel lesen | |
| APNIMED | 18,530 | +0,11 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen |
APOTEX HEALTH CORP gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APOTEX HEALTH CORP finden Sie auf Wallstreet Online.